Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kadence Bio is a clinical-stage biotechnology company developing innovative therapeutics for sexual and mental health conditions. The company’s lead drug candidate, KH-001, is being developed as a potential first FDA-approved treatment for premature ejaculation, addressing a major unmet medical need. In addition, Kadence Bio is advancing a pipeline of novel small-molecule compounds for mood disorders. Through science-driven ...
Kadence Bio is a clinical-stage biotechnology company developing innovative therapeutics for sexual and mental health conditions. The company’s lead drug candidate, KH-001, is being developed as a potential first FDA-approved treatment for premature ejaculation, addressing a major unmet medical need. In addition, Kadence Bio is advancing a pipeline of novel small-molecule compounds for mood disorders. Through science-driven research and clinical development, the company aims to improve intimacy, wellbeing and quality of life for patients worldwide.

List your booth number for exhibitions, ask us